Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma

References

• JemalASiegelRXuJWardECancer statisticsCA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• KyleRARajkumarSVMultiple myelomaN Engl J Med2004351181860187315509819
   PubMed Web of Science ®Google Scholar
• LaubachJPSchlossmanRLMitsiadesCSAndersonKCRichardsonPGThalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myelomaExpert Rev Hematol201141516021322778
   PubMed Web of Science ®Google Scholar
• van de DonkNWLokhorstHMDimopoulosMTreatment of relapsed and refractory multiple myeloma in the era of novel agentsCancer Treat Rev201137426628320863623
   PubMed Web of Science ®Google Scholar
• SinghalSMehtaJDesikanRAntitumor activity of thalidomide in refractory multiple myelomaN Engl J Med1999341211565157110564685
   PubMed Web of Science ®Google Scholar
• AndersonKCLenalidomide and thalidomide: mechanisms of action-similarities and differencesSemin Hematol2005424 Suppl 4S3S816344099
   PubMed Web of Science ®Google Scholar
• HoffmannMKasserraCReyesJAbsorption, metabolism and excretion of [14C] pomalidomide in humans following oral administrationCancer Chemother Pharmacol201371248950123203815
   PubMed Web of Science ®Google Scholar
• RajkumarSVKyleRAAngiogenesis in multiple myelomaSemin Oncol200128656056411740809
   PubMed Web of Science ®Google Scholar
• ReddyNHernandez-IlizaliturriFJDeebGImmunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivoBr J Haematol20081401364517995965
   PubMed Web of Science ®Google Scholar
• DredgeKMarriottJBMacdonaldCDNovel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effectsBr J Cancer200287101166117212402158
   PubMed Web of Science ®Google Scholar
• VaccaAScavelliCMontefuscoVThalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myelomaJ Clin Oncol200523235334534615939924
   PubMed Web of Science ®Google Scholar
• DredgeKHorsfallRRobinsonSPOrally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitroMicrovasc Res2005691–2566315797261
   PubMed Web of Science ®Google Scholar
• HideshimaTChauhanDShimaYThalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyBlood20009692943295011049970
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSPoulakiVApoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsBlood200299124525453012036884
   PubMed Web of Science ®Google Scholar
• NogueiraACNeubertRHelgeHNeubertDThalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cellsLife Sci199455277927516993
   PubMed Web of Science ®Google Scholar
• DaviesFERajeNHideshimaTThalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaBlood200198121021611418482
   PubMed Web of Science ®Google Scholar
• ZhuDCorralLGFlemingYWSteinBImmunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activationCancer Immunol Immunother200857121849185918392823
   PubMed Web of Science ®Google Scholar
• ZhuYXBraggioEShiCXCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideBlood2011118184771477921860026
   PubMed Web of Science ®Google Scholar
• ZhuYXKortuemKMStewartAKMolecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myelomaLeuk Lymphoma201354468368722966948
   PubMed Web of Science ®Google Scholar
• PrattGGoodyearOMossPImmunodeficiency and immunotherapy in multiple myelomaBr J Haematol2007138556357917686051
   PubMed Web of Science ®Google Scholar
• RacanelliVLeonePFrassanitoMAAlterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myelomaBlood201011561185119320008301
   PubMed Web of Science ®Google Scholar
• GoodyearOCPrattGMcLarnonADifferential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myelomaBlood200811283362337218658027
   PubMed Web of Science ®Google Scholar
• DredgeKMarriottJBTodrykSMProtective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunityJ Immunol2002168104914491911994441
   PubMed Web of Science ®Google Scholar
• LuLPayvandiFWuLThe anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditionsMicrovasc Res2009772788618805433
   PubMed Web of Science ®Google Scholar
• Escoubet-LozachLLinILJensen-PergakesKPomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanismCancer Res200969187347735619738071
   PubMed Web of Science ®Google Scholar
• El-DeiryWSTokinoTVelculescuVEWAF1, a potential mediator of p53 tumor suppressionCell19937548178258242752
   PubMed Web of Science ®Google Scholar
• Lopez-GironaAMendyDItoTCereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia201226112326233522552008
   PubMed Web of Science ®Google Scholar
• ScheySAFieldsPBartlettJBPhase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myelomaJ Clin Oncol200422163269327615249589
   PubMed Web of Science ®Google Scholar
• StreetlyMJGyertsonKDanielYZeldisJBKazmiMScheySAAlternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulationBr J Haematol20081411415118324965
   PubMed Web of Science ®Google Scholar
• BladéJSamsonDReeceDCriteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantationMyeloma Subcommittee of the EBMT. European Group for Blood and Marrow TransplantBr J Haematol19981025111511239753033
   PubMed Web of Science ®Google Scholar
• RichardsonPGSiegelDBazRPhase I study of pomalidomide MTD, safety and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomibBlood2013121111961196723243282
   PubMed Web of Science ®Google Scholar
• RichardsonPGWellerELonialSLenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaBlood2010116567968620385792
   PubMed Web of Science ®Google Scholar
• DimopoulosMAKastritisEChristoulasDTreatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapiesLeukemia201024101769177820739955
   PubMed Web of Science ®Google Scholar
• RichardsonPGHofmeisterCCSiegelDMM-005: a phase 1, multicenter, open-label, dose-escalation study to determine the maximum tolerated dose for the combination of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myelomaPaper presented at: 54th Annual Meeting of the American Society of HematologyDecember 8–11, 2012Atlanta, GA, USA
   Google Scholar
• BazRShainKHAlsinaMOral weekly cyclophosphamide in combination with pomalidomide and dexamethasone for relapsed and refractory myeloma: report of the dose escalation cohortPaper presented at: 54th Annual Meeting of the American Society of HematologyDecember 8–11, 2012Atlanta, GA, USA
   Google Scholar
• BerensonJRHilgerJDKleinLMA Phase 1/2 Study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myelomaPaper presented at: 54th Annual Meeting of the American Society of HematologyDecember 8–11, 2012Atlanta, GA, USA
   Google Scholar
• LacyMQHaymanSRGertzMAPomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myelomaJ Clin Oncol200927305008501419720894
   PubMed Web of Science ®Google Scholar
• DurieBGHarousseauJLMiguelJSInternational uniform response criteria for multiple myelomaLeukemia20062091467147316855634
   PubMed Web of Science ®Google Scholar
• LacyMQHaymanSRGertzMAPomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)Leukemia201024111934193920827286
   PubMed Web of Science ®Google Scholar
• JagannathSHofmeisterCCSiegelDSPomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup AnalysisPaper presented at: 54th Annual Meeting of the American Society of HematologyDecember 8–11, 2012Atlanta, GA, USA
   Google Scholar
• LacyMQAllredJBGertzMAPomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory diseaseBlood2011118112970297521690557
   PubMed Web of Science ®Google Scholar
• LeleuXAttalMArnulfBIntergroupe Francophone du MyélomePomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02Blood2013121111968197523319574
   PubMed Web of Science ®Google Scholar
• ShortKDRajkumarSVLarsonDIncidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myelomaLeukemia201125690690821350560
   PubMed Web of Science ®Google Scholar
• DimopoulosMALacyMQMoreauPPomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory mm: a phase 3, multicenter, randomized, open-label studyPaper presented at: 54th Annual Meeting of the American Society of HematologyDecember 8–11, 2012Atlanta, GA, USA
   Google Scholar